

Supplementary table1. Comparison of clinicopathologic characteristics between patients studied (N=188) and patients not studied (N=934) from E2290 study

	In this study	Not in this study	<i>P</i> value
Male (%)	65%	61%	0.26
Age>65 (%)	50%	40%	0.02
White (%)	89%	84%	0.29
Distal cancer (%)	65%	61%	0.28
With Liver Mets (%)	77%	77%	0.85
With Nodal Mets (%)	38%	35%	0.36
PS-0 (%)	50%	46%	0.52

Supplementary Table 2. Correlation between methylation of each marker by Spearman correlation analysis (r and *P* value-two tailed)

	MINT1	MINT2	MINT31	P16	P14	hMLH1
MINT1		0.15 N.S.	0.24 ( <i>P</i> =0.002)	0.23 ( <i>P</i> =0.003)	0.20 ( <i>P</i> =0.009)	0.07 N.S.
MINT2			0.12 N.S.	0.11 N.S.	-0.07 N.S.	0.03 N.S.
MINT31				0.47 ( <i>P</i> <0.0001)	0.30 ( <i>P</i> <0.0001)	0.20 ( <i>P</i> =0.008)
P16					0.19 ( <i>P</i> =0.01)	0.07 N.S.
P14						0.41 ( <i>P</i> <0.0001)

N.S.: not statistically significant

Supplementary table3. The adjustment covariates with their HR/*P* values used in multivariate analysis model

Covariate	MINT1	MINT2	MINT31	P16	P14	MLH1	SUM	MITN31+P16+P14
Location (distal)	1.57/.019	1.65/.007	1.79/.003	1.69/.004	1.68/.006	1.65/.008	1.60/.010	1.61/.022
Liver Mets	0.91/.68	0.97/.91	0.96/.83	1.01/.97	0.94/.78	0.98/.91	0.95/.81	0.92/.71
Node Mets	1.14/.50	1.24/.23	1.12/.30	1.25/.21	1.21/.29	1.26/.21	1.22/.27	1.15/.48
PS=1	2.43/<.0001	2.01/.0002	2.10/.0001	1.97/.0003	1.88/.001	2.00/.0003	2.03/.0002	2.30/<.0001
PS=2	7.69/<.0001	5.52/<.0001	5.85/<.0001	4.84/<.0001	4.92/<.0001	5.50/<.0001	5.31/<.0001	6.02/<.0001
Gender (male)	0.82/.34	1.03/.87	1.12/.54	1.09/.64	1.01/.94	1.04/.85	1.08/.66	0.98/.90
Age>65	1.05/.82	1.08/.67	1.06/.76	1.07/.71	1.13/.48	1.11/.57	1.09/.63	1.07/.73
Black vs White	1.16/.69	0.96/.90	0.97/.94	0.99/.98	1.00/.99	0.99/.97	0.98/.96	1.25/.55
Hispanic vs White	0.65/.30	0.87/.70	1.27/.55	0.80/.53	0.77/.49	0.85/.66	0.88/.73	0.69/.44